Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

NEW YORK, May 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

http://www.reportlinker.com/p0606218/Neuroendocrine-Carcinoma-Therapeutics---Pipeline-Assessment-and-Market-Forecast-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

Summary GlobalData, the industry analysis specialist, has released its new report, "Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019". The report is an essential source of information and analysis on the global neuroendocrine carcinoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019. The high growth is primarily attributed to the advent of approved drugs, Sutent (sunitinib) and Afinitor (everolimus), in the major markets. The expected launch of promising drugs in the forecast period will drive the market. The promising drugs to be launched include: Avastin (bevacizumab) and Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) for Gastrointestinal (GI) carcinoid and pancreatic Neuroendocrine Tumors (NETs), pasireotide (SOM 230), and Somatuline (lanreotide acetate) Autogel/Depot for GI carcinoids NETs. These factors will accelerate the growth of the neuroendocrine carcinoma therapeutics market.

Scope

- Annualized data on the seven key neuroendocrine carcinoma markets (the US, France, Germany, Italy, Spain, the UK and Japan) revenue data from 2006 to 2011, forecast for eight years to 2019.- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends in the market. Pipeline candidates fall under the following mechanisms of action: Somatostatin analogues and Vascular Endothelial Growth Factor (VEGF) inhibitors, insulin-like growth factor-1 receptor (IGFR-1) inhibitors, tyrosine kinase inhibitor (TKI) and Smoothened (Smo) inhibitor.- Analysis of the current and future competition in the global neuroendocrine carcinoma market. Key market players covered are Novartis AG, Roche, the Eli Lilly & Company, Callisto Pharmaceuticals, Molecular Insight pharmaceuticals, Advanced Accelerator Applications S.A, Roche, Ipsen and Amgen Inc.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.- Key topics covered include a strategic competitor assessment, market characterization, and unmet needs and their implications for the neuroendocrine carcinoma therapeutics market.- Analysis of key recent licensing and partnership agreements in the neuroendocrine carcinoma market.

Reasons to buy

The report will enhance your decision-making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.- Develop business strategies by understanding the trends shaping and driving the global neuroendocrine carcinoma market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global neuroendocrine carcinoma market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What is the next big thing in the global neuroendocrine carcinoma market landscape? Identify, understand and capitalize.1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Neuroendocrine Carcinoma Therapeutics - Introduction 72.1 Disease Overview 72.2 Epidemiology 92.3 Risk Factors 102.4 Etiology 112.5 Symptoms 112.6 Diagnosis 122.7 Staging 162.8 Treatment and Management Pattern 192.8.1 Treatment Algorithm 192.8.2 Treatment for GI Carcinoid Tumors 192.8.3 Treatment for Pancreatic NETs/Islet Cell Tumor 212.9 Referral Pathway for GEP-NETs 222.10 GlobalData Pipeline Report Guidance 243 Neuroendocrine Carcinoma Therapeutics- Market Characterization 253.1 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Global 253.2 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) – Global 273.3 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – the US 293.4 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the US 303.5 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) –the UK 313.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK 323.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France 333.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France 343.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany 353.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany 363.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy 373.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy 383.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain 393.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain 403.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan 413.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan 423.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market 433.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market 433.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market 433.18 Key Events Impacting the Future Market 443.19 Opportunity and Unmet Need 443.19.1 Gastrointestinal carcinoid (NETs) 453.19.2 Pancreatic NETs 453.20 Key Takeaway 464 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment 474.1 Overview 474.1.1 Strategic Competitor Assessment 474.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma 494.2.1 Afinitor (everolimus, RAD001) 494.2.2 Sutent (sunitinib) 504.2.3 Sandostatin LAR (octreotide acetate) 514.3 Key Takeaway 515 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 525.1 Overview 525.2 Strategic Pipeline Assessment 525.3 Analysis by Phase of Development 535.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline 535.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline 545.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline 545.3.4 Neuroendocrine Carcinoma Therapeutics - Preclinical Pipeline 545.4 Neuroendocrine Carcinoma Therapeutics- Clinical Pipeline by Mechanism of Action 555.5 Technology Trends Analytic Framework 555.6 Neuroendocrine Carcinoma Therapeutics - Key Late Stage Pipeline Drugs in Clinical Development 585.7 Molecule Profile for Key Late Stage Pipeline Drugs under Clinical Development 585.7.1 Avastin (bevacizumab) 585.7.2 Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) 595.7.3 Paseriotide (SOM 230) 605.7.4 Somatuline Autogel (lanreotide acetate) 615.8 Key Takeaway 616 Neuroendocrine Carcinoma Therapeutics - Clinical Trials Mapping 626.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 626.2 Clinical Trials by Phase 636.3 Clinical Trials by Trial Status 646.4 Prominent Sponsors 656.5 Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 677 Neuroendocrine Carcinoma Therapeutics- Strategic Assessment 687.1 Future Market Competition Scenario 688 Neuroendocrine Carcinoma Therapeutics - Future Players 708.1 Introduction 708.2 Company Profiles for the Promising Drugs 708.2.1 Advanced Accelerator Applications S.A 708.2.2 Novartis AG 718.2.3 F. Hoffmann-La Roche 738.2.4 Ipsen SA 748.3 Other Companies in the Neuroendocrine Carcinoma Therapeutics Market 769 Neuroendocrine Carcinoma Therapeutics- Licensing and Partnership Deals 7710 Neuroendocrine Carcinoma Therapeutics - Appendix 7910.1 Market Definitions 7910.2 Abbreviations 7910.3 Methodology 8010.3.1 Coverage 8110.3.2 Secondary Research 8110.3.3 Forecasting 8110.3.4 Primary Research 8310.3.5 Expert Panel Validation 8410.4 Contact Us 8410.5 Disclaimer 8410.6 Bibliography 84

List of Tables

Table 1: GEP-NETs WHO Classification 7Table 2:GEP-NETs Classification 8Table 3: Historical Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 9Table 4: Forecast Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 10Table 5: Symptoms of Pancreatic NETs/Islet Cell Tumors 12Table 6:Diagnosis Techniques by Site of Origin for GI Carcinoid Tumors 14Table 7:Diagnosis Tests for Different Types of Functioning Pancreatic Neuroendocrine Tumors 15Table 8:TNM Classification of Stomach Carcinoid Tumors 16Table 9:TNM Classification of Duodenum Carcinoid Tumors 17Table 10:TNM Staging of Appendiceal Carcinoid Tumors 17Table 11:TNM Classification of Pancreatic Neuroendocrine Tumors 18Table 12:TNM Staging for Pancreatic Neuroendocrine Tumors 18Table 13:Chemotherapy Regimens in GEP-NETs Carcinoma 22Table 14: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006–2011 25Table 15: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Market Forecast ($m), 2011-2019 28Table 16:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006–2011 29Table 17: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 30Table 18:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006–2011 31Table 19: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 32Table 20:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue($m), 2006–2011 33Table 21: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 34Table 22:Neuroendocrine Carcinoma Therapeutics Market,Germany, Revenue ($m), 2006–2011 35Table 23: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 36Table 24:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue($m), 2006–2011 37Table 25: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 38Table 26:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006–2011 39Table 27:Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 40Table 28:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006–2011 41Table 29: Neuroendocrine Carcinoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 42Table 30:Neuroendocrine Carcinoma Therapeutics – Phase III Pipeline, 2012 53Table 31:Neuroendocrine Carcinoma Therapeutics – Phase II Pipeline, 2012 54Table 32:Neuroendocrine Carcinoma Therapeutics – Phase I Clinical Pipeline, 2012 54Table 33:Neuroendocrine Carcinoma Therapeutics – Preclinical Pipeline, 2012 54Table 34: Neuroendocrine Carcinoma Therapeutics –Phase III Promising Drugs in Clinical Development 58Table 35:Adverse events of Bevacizumab and Peginterferon alfa-2b 59Table 36:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Region/Country, 2012 62Table 37:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012 63Table 38:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012 64Table 39:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Overall Sponsors, 2012 65Table 40: Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Prominent Sponsors, 2012 66Table 41: Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012 67Table 42: Advanced Accelerator Applications S.A. – Neuroendocrine Carcinoma Pipeline Product, 2012 71Table 43:Novartis AG – Oncology Pipeline Products, 2012 72Table 44:Novartis AG – Neuroendocrine Carcinoma Pipeline Product, 2012 72Table 45:F. Hoffmann-La Roche- Oncology Pipeline Products, 2012 74Table 46:F. Hoffmann-La Roche – Neuroendocrine Carcinoma Pipeline Product, 2012 74Table 47:Ipsen SA- Oncology Pipeline Products, 2012 75Table 48:Ipsen SA- Neuroendocrine Carcinoma Pipeline Product, 2012 75Table 49:Neuroendocrine Carcinoma Therapeutics – Other Future Players, 2012 76Table 50:Neuroendocrine Carcinoma Therapeutics, Global, Deals ($m), 2012 77

List of Figures

Figure 1: Patient Share of Neuroendocrine Carcinoma* in the Seven Major Markets, 2011 9Figure 2:Treatment Algorithm for GEP-NETs 19Figure 3:Referral Pathway for GEP-NETs 23Figure 4: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011 25Figure 5:Neuroendocrine Carcinoma Therapeutics , Market Share (%), 2011 26Figure 6: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Forecast ($m), 2011-2019 27Figure 7:Neuroendocrine Carcinoma Therapeutics, Market Share (%), 2019 28Figure 8:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006-2011 29Figure 9: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 30Figure 10:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006-2011 31Figure 11: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 32Figure 12:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue ($m), 2006-2011 33Figure 13: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 34Figure 14:Neuroendocrine Carcinoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 35Figure 15: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 36Figure 16:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 37Figure 17: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 38Figure 18:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 39Figure 19: Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 40Figure 20:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 41Figure 21: Neuroendocrine Carcinoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 42Figure 22:Neuroendocrine Carcinoma Therapeutics – Drivers and Barriers, 2012 44Figure 23:Opportunities and Unmet Need in the GI Carcinoid NETs Therapeutics Market 45Figure 24:Opportunities and Unmet Need in Pancreatic NETs Therapeutics Market 46Figure 25: Strategic Competitor Assessment of the Major Marketed Products in GI Carcinoid NETs, 2012 48Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Pancreatic NETs, 2012 49Figure 27: Neuroendocrine Carcinoma Therapeutics Pipeline by Phase of Clinical Development, 2012 53Figure 28: Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Mechanism of Action, 2012 55Figure 29: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline, 2012 56Figure 30: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline – Description, 2012 57Figure 31:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Region/Country, 2012 62Figure 32:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012 63Figure 33:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012 64Figure 34:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Overall Sponsors, 2012 65Figure 35: Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Prominent Sponsors, 2012 66Figure 36:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012 67Figure 37:GI Carcinoids NETs Therapeutics – Implications for Future Market Competition, 2012 68Figure 38:Pancreatic NETs Therapeutics – Implications for Future Market Competition, 2012 69Figure 39:Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Company, 2012 70Figure 40- GlobalData Market Forecasting Model 83

Companies mentioned

Advanced Accelerator Applications S.A

Novartis AG

F. Hoffmann-La Roche

Ipsen SA

To order this report:Therapy Industry: Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelisā„¢ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... Inc. (NYSE MKT: ISR), a medical technology company and ... the treatment of prostate, brain, lung, head and neck ... the second quarter and six months of fiscal 2016, ... --> --> Revenue was $1.19 million ... December 31, 2015, a 12% increase compared to $1.07 ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... states, announced today the promotion of two long-standing principal investigators (PI) to the ... Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research PI ...
(Date:2/10/2016)... Charlotte, NC (PRWEB) , ... February 10, 2016 ... ... highly anticipated expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. ... Sonablate® HIFU procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
Breaking Biology News(10 mins):